Pfiz­er earns long-await­ed full FDA nod for Covid-19 vac­cine, a hope­ful aid in US cam­paign

The FDA on Mon­day an­nounced its full ap­proval for Pfiz­er and BioN­Tech’s mR­NA-based Covid-19 vac­cine for in­di­vid­u­als 16 and old­er, po­ten­tial­ly of­fer­ing a break­through on the PR front for the US vac­ci­na­tion cam­paign.

The vac­cine, which pre­vi­ous­ly held an emer­gency use au­tho­riza­tion from the agency, will now mar­ket as Comir­naty — a moniker the com­pa­nies had pre­vi­ous­ly an­nounced, chang­ing from the place­hold­er “Pfiz­er-BioN­Tech Covid-19 Vac­cine” name. Chil­dren be­tween the ages of 12 and 16 will still have ac­cess to the vac­cine un­der the EUA and tri­als in chil­dren younger than 12 are still on­go­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER